Top Banner
ASSESSMENT OF FOETAL WELL BEING ANTEPARTUM AND INTRAPARTUM DR RAJEEV SOOD ASSOC. PROF. OBG KAMLA NEHRU HOSPITAL INDIRA GANDHI MEDICAL COLLEGE SHIMLA
132
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Antepartum and intrapartum foetal monitoring

ASSESSMENT OF FOETAL WELL BEING ANTEPARTUM AND INTRAPARTUM

DR RAJEEV SOOD ASSOC. PROF. OBG

KAMLA NEHRU HOSPITAL

INDIRA GANDHI MEDICAL COLLEGE SHIMLA

Page 2: Antepartum and intrapartum foetal monitoring

INTRODUCTION ANTENATAL FETAL SURVEILLANCE IS

ASSESSMENT OF FETAL WELL BEING INANTEPARTUM PERIOD TO ENSUREDELIVERY OF HEALTHY NEONATE.

Two main objectives are:-

Early detection of fetuses at risk toprevent perinatal mortality andmorbidity.

Find out normal fetuses and avoidunwarranted interventions.

2

Page 3: Antepartum and intrapartum foetal monitoring

ANTEPARTUM FETAL ASSESSMENT METHODS:- 1a CLINICAL ASSESSMENT Weight gain Fundal height Abdominal girth Auscultation of fetal heart 1b fetal movement count by mother 2.ultrasound for fetal parameters 3.biochemical tests 4.NST 5.VAST 6.CST

3

Page 4: Antepartum and intrapartum foetal monitoring

7.Nipple stimulation test

8.biophysical profile

9.doppler

10.fetal lung maturation test

11.placental grading

4

Page 5: Antepartum and intrapartum foetal monitoring

INDICATIONS MATERNAL FETAL PREGNANCY RELATED MATERNAL Hypertension Diabetes Heart disease Chronic renal disease Sever anemia APLA Acute illnesses

5

Page 6: Antepartum and intrapartum foetal monitoring

Fetal

Fetal growth restriction

Rh isoimmunisation

Fetal cardiac arrythmias

Fetal infections

6

Page 7: Antepartum and intrapartum foetal monitoring

PREGNANCY RELATED Multiple pregnancy

Gestational hypertension

Preeclampsia

Decreased fetal movement

Abnormal placentation

Placental abruption

Amniotic fluid disorders

PROM

GDM

Previous unexplained still birth

ICP

Post term pregnancy

7

Page 8: Antepartum and intrapartum foetal monitoring

WHEN TO START? Depends up on factors like:-

Past history of adverse outcome

Severity of maternal and fetal conditions

Generally Monitoring is recommended whenestimated fetal maturity is sufficient to expect areasonable chance of survival should intervention benecessary.

8

Page 9: Antepartum and intrapartum foetal monitoring

CLINICAL ASSESSMENT

WEIGHT GAIN

9

Recommended Ranges of Weight GainDuring Singleton Gestations Stratified by Pre pregnancy Body Mass Index

Category BMI Wt. in kgsLow 19.8 12.5–18Normal 19.8–26 11.5–12.5High 26–29 7–11.5Obese 29 7

Page 10: Antepartum and intrapartum foetal monitoring

Symphysio-fundal height Measured from superior border of

pubis symphysis to fundus

From 24th wks of gestation corresponds to period of gestation .

Difference of 2- 3 cms acceptable

below 10th percentile or difference of >4cms suggests IUGR

positive predictive value of 60% negative predictive value of 76.8%

10

Page 11: Antepartum and intrapartum foetal monitoring

Abdominal girth Measured at lower border of umbilicus.

Increases by 2.5cm per week after 30wks.

95-100 cms at term.

Static or falling values alarming sign.

11

Page 12: Antepartum and intrapartum foetal monitoring

Fetal movement count

Cardiff” count 10” technique

Daily fetal movement count

Perception of three movement in 30 minutes.

12

Page 13: Antepartum and intrapartum foetal monitoring

Fetal movement count Fetus spends 10% of its time making gross fetal

body movements

Periods of active fetal body movement last about 40 minutes

Longest period without fetal movements about 75 minutes.

Mother appreciate 70% to 80% of gross fetal movements.

13

Page 14: Antepartum and intrapartum foetal monitoring

Fetal movement peak between 9:00 PM and 1:00 AM.

Time when maternal glucose levels are falling.

Fetal activity does not increase after meals or after maternal glucose administration.

14

Page 15: Antepartum and intrapartum foetal monitoring

Factors affecting maternal perception of fetal movement Fetal and placental factors :-

Placental location

The length and type of fetal movements

Amniotic fluid volume (AFV)

Maternal factors :-

Parity, obesity.

Psychological factors anxiety.

15

Page 16: Antepartum and intrapartum foetal monitoring

ULTRASOUND FOR FETAL PARAMETERS HIGH RESOLUTION UTRASOUND

REVOLUTIONIZED PRENATAL DIAGNOSIS.

CAN BE:-

BASIC

TARGETED

BASIC:-(in early pregnancy)

Done at 10-14wks and includes :-

No. of fetuses

Fetal life

Placental localization

Internal os diameter

Cervical length16

Page 17: Antepartum and intrapartum foetal monitoring

Gestational age

maternal pelvic masses

Any gross anomaly like anencephaly,limbreduction defects.

Nuchal translucency(80% fetuses with 5% false positive rates)

Only in high risk patients

17

Page 18: Antepartum and intrapartum foetal monitoring

CRL smaller than gestational age

chromalsomal anomalies

Absencence of nasal bone at 10-12wks

Down syndrome

NB+NT detection rate of 92% & false positive rate of 3.5%

18

Page 19: Antepartum and intrapartum foetal monitoring

2nd &3rd triemester Serial measurements of BPD,AC,HC,FL.

HC/AC ratio exceeds 1 before 32wks.

1 bw 32to 34wks. After 34wk falls below 1.

In symmetric IUGR remains normal.

Ratio can identify 85% IUGR fetuses.

FL/AC remains 22 at all gestational ages from 21wks to term. >23.5 suggest IUGR.

AC remains single best parameter to detect IUGR with positive predictive value of 50%.

Trans cerebellar diameter in mm corresponds to POG from 11wks –32wks .

19

Page 20: Antepartum and intrapartum foetal monitoring

AMNIOTIC FLUID VOLUME Single deepest pocket >2cm normal

Or

Amniotic fluid index 5-25cm.

20

Page 21: Antepartum and intrapartum foetal monitoring

Targetted ultrasound Done in high risk patients

In developed countries offered to all patients

Transverse section for fetal head

Shape and internal structures. BPD,HC Measured to detect hydrocephalus,anencephaly

Transverse and longitudinal views of abdomen to rule out anomalies of stomach, kidneys ,bladder, ventral wall.

Transverse section of fetal thorax to four chambered view of heart.

21

Page 22: Antepartum and intrapartum foetal monitoring

Four chambered view of heart

22

Page 23: Antepartum and intrapartum foetal monitoring

Identify three long bones in each limb

and any achondroplasia is looked for.

Saggittal ,coronal and transverse views taken to rule out spinabifida.

cephalic index

Biparietal diameter/occipitofrontal diameter

23

Page 24: Antepartum and intrapartum foetal monitoring

Fetal ECHO IndicationsFetal risk factors Suspected cardiac anomaly on level I scan

• Nuchal thickening/lucency• Diaphragmatic hernia• Duodenal atresia• Tracheoesophageal fistula• Cystic hygroma

Chromosomal abnormalities

Twin–twin transfusion• Acardiac twin• Vein of Galen aneurysm

24

Page 25: Antepartum and intrapartum foetal monitoring

Maternal risk factors •

Congenital heart disease• Exposure to teratogen

Diabetes

Maternal infectionsFamilial risk factors• Trisomy 21 (Down)

25

Page 26: Antepartum and intrapartum foetal monitoring

Historically optimal timing between 18 and 22 weeks’ gestation.

moving into an era of early risk assessment .

fetal echocardiography late first and early second trimesters

A limited number of reports describe the utility of transvaginal imaging between 10 and 13 weeks.

26

Page 27: Antepartum and intrapartum foetal monitoring

Non stress test Freeman first described the NST in 1975.

Physiologic premise of the NST is that:-

Nonhypoxic fetus

stimulus

accelerate its heart rate

27

Page 28: Antepartum and intrapartum foetal monitoring

Method FHR and uterine activity are monitored with

an external transducer

FHR is monitored for 20 minutes.

For 40 minutes in some cases to compensates for sleep cycles then called EXTENDED NST.

In some cases when the fetus is not reactive, acoustic stimulation by artificial larynx a sound stimulus for 1 to 2 seconds.

28

Page 29: Antepartum and intrapartum foetal monitoring

INTERPRETATION Reactive NST presence of two accelerations of

15bpm over base line for 15sec in a 20-minute time period with or without fetal movements.

Nonreactive NST absence of two accelerations in a 40-minute period with or without acoustic stimulation over a 40-minute period.

29

Page 30: Antepartum and intrapartum foetal monitoring

NST is not routinely started until 32-weeks gestation.

Up to 50% of NSTs reactive from 24- to 28-weeks gestation.

85% from 28 to 32 weeks of gestation In up to 50% of NSTs variable decelerations

may be observed. It last for <30 seconds and <2 during a 20-

minute period

NO fetal compromise

30

Page 31: Antepartum and intrapartum foetal monitoring

PREDICTIVE VALUE With a reactive NST, the chance for fetal death

within 1 week is 1.9 per 1,000, giving a negative predictive value of 99.8% after correction for lethal anomalies.

Best senstivity and positive predictive value for IUGR and Hypertensive disorders -70%

Reactive NST is reassuring.

Nonreactive NST is nonspecific and requires further evaluation.

31

Page 32: Antepartum and intrapartum foetal monitoring

The false-positive rate is considerably higher, ranging from 50% to more than 90% in various studies.

In high-risk pregnancies, the false-negative rate associated with a weekly NST may be unacceptably high.

In these cases, increasing frequency of the NST to twice weekly may be considered.

32

Page 33: Antepartum and intrapartum foetal monitoring

VIBROACOUSTIC STIMULATION TEST Used as an adjunct to NST

If NST non reactive even after 40min then:-

Continue CTG monitoring till 90min

OR

Perform BPP

OR

VAST

33

Page 34: Antepartum and intrapartum foetal monitoring

Auditory brainstem response functional at 26 to 28 weeks’ gestation.

VAST increase the incidence of reactive NSTs after 26 weeks’ gestation .

Reduce the testing time.

artificial larynx that generates sound 82 Db -100db with a frequency of 80 Hz.

34

Page 35: Antepartum and intrapartum foetal monitoring

A stimulus for 3 seconds or less is applied near the fetal head.

If the NST remains nonreactive

Stimulus is repeated at 1-minute intervals up to three times.

35

Page 36: Antepartum and intrapartum foetal monitoring

VAST have shown a decreased incidence of nonreactive NSTs from 13% to 14% down to 6% to 9%.

36

Page 37: Antepartum and intrapartum foetal monitoring

MANAGEMENT PROTOCOL OF NSTNST for 20 min Reactive

Repeate after 1wk Or earlier if situation demands

If non reactive Extend to 40min

Non reactive VAST Non reactive BPP

37

Page 38: Antepartum and intrapartum foetal monitoring

BIOPHYSICAL PROFILE Thorough evaluation of fetal well-being .

Potential to significantly reduce the false-positive rate of the NST/CST.

The BPP was initially described by Manning and colleagues .

Rationale:-Fetal biophysical activities controlled by centers in the fetal brain sensitive to varying degrees of hypoxia.

38

Page 39: Antepartum and intrapartum foetal monitoring

BPP SCORING( MANNING)

1. Movements Three or more gross body movements SCORE

in a 30-minute period.

Simultaneous trunk and limb 2

movements count as a single

Movement

Fewer than 3 gross body movements 0

in a 30-minute period

39

Page 40: Antepartum and intrapartum foetal monitoring

SCORE

2. TONE At least one movement of a limb from

a position of flexion to one of extension, 2

with a rapid return to flexion.

Fetal limb in extension with no return 0

to flexion with movement

3.Breathing At least 30 seconds of sustained

FBMs observed over a 30-minute period 2

Fewer than 30 seconds of sustained

FBMs observed over a 30-minute 0

40

Page 41: Antepartum and intrapartum foetal monitoring

SCORE

4.AFPAt least a single amniotic fluid pocket

measuring 2 cm in 2 perpendicular planes 2

No amniotic fluid pocket that 0

measures at least 2 cm

2 perpendicular planes

5. NST reactive 2

NST non reactive 0

41

Page 42: Antepartum and intrapartum foetal monitoring

Technique Performance of an NST.

For gestations less than 32 weeks, the qualifying criteria for accelerations are greater than 10 bpm, lasting at least 10 seconds.

42

Page 43: Antepartum and intrapartum foetal monitoring

MANAGEMENT PROTOCOL OF BPP 10 Normal; low risk for chronic asphyxia Repeat testing

at weekly to twice-weekly intervals (IN HIGH RISK CASES)

8 Normal; low risk for chronic asphyxia Repeat testing at weekly to twice-weekly intervals If oligohydroamniosdeliver.

6 Suspect chronic asphyxia If ≥36-37 wk gestation or <36 wk with positive testing for fetal pulmonary maturity, consider delivery. Otherwise repeat with in 24hrs

if <36 wk and/or fetal pulmonary maturity testing negative, repeat biophysical profile in 4 to 6 hr.

deliver if oligohydramnios is present

43

Page 44: Antepartum and intrapartum foetal monitoring

4 Suspect chronic asphyxia If ≥36 wk gestation, deliver.

if <32 wk gestation, repeat with in 24hrs. If repeat score <6 deliver if >6 observe.

0-2 Strongly suspect chronic asphyxia Extend testing time to 120 min.

if persistent score ≤4, deliver, regardless of gestational age

44

Page 45: Antepartum and intrapartum foetal monitoring

NST and FBM Has highest senstivity

Fetal tone has highest specificity

45

Page 46: Antepartum and intrapartum foetal monitoring

MODIFIED BPP Attempt to simplify and reduce the time.

Focusing on the components of the BPP most predictive of perinatal outcome.

Two parameters:-

1. NST indicator of present fetal condition.

2. AFI /AFP a marker of long-term status.

46

Page 47: Antepartum and intrapartum foetal monitoring

Contraction Stress Test

CST/OCT first biophysical technique widely applied for antepartum fetal surveillance.

Principle

uterine contractions

Reduction in blood flow to the intervillous space.

Inadequate placental respiratory reserve

Recurrent late decelerations in response to hypoxia.

47

Page 48: Antepartum and intrapartum foetal monitoring

TECHNIQUEFetal heart rate and uterine contraction baseline is

determined.

Blood pressure is recorded every 5 to 10 minutes to detect maternal hypotension.

oxytocin started @.5-1 miu /min.

An adequate CST requires uterine contractions of moderate intensity lasting about 40 to 45 seconds with a frequency of three in 10 minutes.

48

Page 49: Antepartum and intrapartum foetal monitoring

INTERPRETATIONNegative: No late or significant variable

decelerations

Positive: Late decelerations with at least 50% of contractions

Suspicious: Intermittent late or variable decelerations

Hyperstimulation: Decelerations with contractions longer than 90 seconds’ duration or 2-minute frequency

Unsatisfactory: Fewer than three contractions per 10 minutes or an uninterpretable tracing

49

Page 50: Antepartum and intrapartum foetal monitoring

PREDICTIVE VALUE OF CST A negative CST good fetal outcome.

incidence of perinatal death within 1 week of a negative CST (i.e., the false-negative rate) to be less than 1 per 1000.

50

Page 51: Antepartum and intrapartum foetal monitoring

MANAGEMENT PROTOCOL OF CST Positive CST is usually repeated in 24 hours .

This is of historical importance .

Not used now.

Page 52: Antepartum and intrapartum foetal monitoring

CONTRAINDICATIONS Placenta previa

Previous CS

Multiple gestation

Polyhydroamnios

History of preterm

Incompetent cervix

52

Page 53: Antepartum and intrapartum foetal monitoring

Nipple stimulation test Alternative method of performing CST

ACOG Recommends stimulation through light clothing for two minutes at a time with rest interval of five minutes.

Adequate uterine contractions obtained with in four minutes of stimulation.

53

Page 54: Antepartum and intrapartum foetal monitoring

DOPPLER VELOCIMETRY Noninvasive technique to assess blood flow by

characterizing downstream impedance

Three fetal and one maternal vascular circuits :-

Umbilical artery,

Middle cerebral artery

Ductus venosus

Uterine artery

54

Page 55: Antepartum and intrapartum foetal monitoring

INDICATIONS IUGR

PIH

GDM

RH ISOIMMUNISATION

INTRAHEPATIC CHOLISTASIS OF PREGNANCY

55

Page 56: Antepartum and intrapartum foetal monitoring

UTERINE ARTERY

INDICATIONS

(1) history of Preeclampsia

(2) previous child with IUGR

(3) unexplained high maternal

serum alpha-fetoprotein level

(4) high human chorionic gonadotropin

level.

(5) thrombophilias

56

Page 57: Antepartum and intrapartum foetal monitoring

The indices used to quantify uterine artery

systolic (S) to diastolic (D) velocity ratio (S/D)

pulsatility index (PI)

resistive index (RI)

early diastolic notching.

Abnormalities in these indices are defined as PI or RI above a chosen value and/or percentile

the presence of unilateral or bilateral diastolic notches

57

Page 58: Antepartum and intrapartum foetal monitoring

How to calculate indices S/D ratio

systolic peak velocity/diastolic peak velocity

Resistance index (RI)

systolic- end diastolic peak velocity/systolic peak velocity

Pulsatility index (PI)

systolic-end diastolic peak velocity/time averaged maximum −velocity

58

Page 59: Antepartum and intrapartum foetal monitoring

Uterine Doppler screening is commonly performed around 20 weeks.

increased uterine artery impedance to flow at 20–24 weeks follow-up at 26–28 weeks.

Cut-off values at 23 weeks' gestation are:-

a mean PI above 1.5–1.61.

mean RI above 0.57–0.58.

Bilateral notches are found in about 25–30% of pregnancies at 12 weeks.

10–15% at 20 weeks .

5% at 24 weeks.

Page 60: Antepartum and intrapartum foetal monitoring

sensitivity is up to 85% when performed between 22 and 23 weeks’ gestation.

high risk patients given low-dose aspirin because of bilateral uterine artery notching at 12 to 14 weeks have an 80% reduction of placental disease

60

Page 61: Antepartum and intrapartum foetal monitoring

An early diastolic notch in the uterine arteries at 12 to 14 weeks suggest delayed trophoblastinvasion.

Persistence “notching” beyond 24 weeks

confirmatory evidence.

61

Page 62: Antepartum and intrapartum foetal monitoring

62

Page 63: Antepartum and intrapartum foetal monitoring

sensitivities and specificities of uterine artery Doppler in low-risk populations varied from 34% to 76% and 83% to 93%, respectively.

63

Page 64: Antepartum and intrapartum foetal monitoring

For both preeclampsia and IUGR uterine artery Doppler more accurate in the second than the first trimester.

Increased PI with notching in the second trimester best predictor of preeclampsia.

64

Page 65: Antepartum and intrapartum foetal monitoring

65

Page 66: Antepartum and intrapartum foetal monitoring

Wave forms at 16,20,24,28,32,36 wks

66

Page 67: Antepartum and intrapartum foetal monitoring

Reverse end diastolic flow

67

Page 68: Antepartum and intrapartum foetal monitoring

FACTS SHEET RI had the best discriminatory

ability when compared with the S/D ratio (P<.05),the PI (P<.001).S/D ratio, however, remains the most popularindex.

S/D ratio less than or equal to 3.0. Resistance index less than or equal

to 0.6 is considered normal after 27 completedweeks of pregnancy.

Benefits of this technique before 28 weeks ofgestation are uncertain.

68

Page 69: Antepartum and intrapartum foetal monitoring

Diagnostic feature of umbilical artery Doppler waveform is the end diastolic flow.

Absent or reverse end diastolic flow ominous finding.

frequency of absent end diastolic flow is approximately 2% in high-risk pregnancies .

0.3% in a general obstetric population.

In pregnancies complicated with FGR, fetal surveillance should consist of weekly umbilical Doppler.

.

69

Page 70: Antepartum and intrapartum foetal monitoring

BPP or NST should be used either as a backup test or simultaneously with the umbilical artery Doppler.

Umbilical Doppler index is high or increasing

weekly umbilical Doppler ultrasound

+

Twice wkly NST/ BPP

70

Page 71: Antepartum and intrapartum foetal monitoring

MANAGEMENT WITH ABSENT END DIASTOLIC FLOW

Guided by the gestational age. >34 completed weeks Delivery

Bw 28 to 34 completed conservative

Daily umbilical artery Doppler, NST, and BPP (or modified BPP)+ Ductus venosus

Reverse flow at any gestational age beyond 28 weeks Delivery

71

Page 72: Antepartum and intrapartum foetal monitoring

MIDDLE CEREBRAL ARTERYTwo major applications Monitoring of IUGR fetuses

Evaluate peak systolic flow in fetuses at risk for anaemia.

72

Page 73: Antepartum and intrapartum foetal monitoring

MCA in Fetal Growth Restriction Hypoxia-induced cerebrovascular dilation

Impedance decreases

Increases end-diastolic blood flow

73

Page 74: Antepartum and intrapartum foetal monitoring

Contrast to fetuses with normal growth

Resistance of the MCA is usually higher than in the umbilical artery.

MCA Doppler useful to monitor the third-trimester growth restricted Fetus.

Redistribution may occur in the presence of normal umbilical Doppler.

RI and PI on MCA Doppler in IUGR fetuses

74

Page 75: Antepartum and intrapartum foetal monitoring

TECHNIQUE Measured at internal third of the vessel

50 to 100 waveforms in at least 3 sets examined.

Impedance to flow decreases and maximum blood velocity increases with advancing gestation.

75

Page 76: Antepartum and intrapartum foetal monitoring

MCA-PSV new development.

better parameter in the prediction of perinatalmortality than PI/RI.

MCA PI in IUGR fetuses can normalize in later stages.

MCA-PSV becomes abnormal, remains as such.

Ratio of MCA PI to Umbilical PI >1.5

in normal fetal circulatory condition.

76

Page 77: Antepartum and intrapartum foetal monitoring

u

77

Page 78: Antepartum and intrapartum foetal monitoring

MCA DOPPLER IN FETAL ANEMIA

RH isoimmunization

Parvovirusinfection

fetomaternal haemorrhage

78

Page 79: Antepartum and intrapartum foetal monitoring

Anemic fetus increased cardiac output

Associated with lower blood viscosity.

So increased blood velocities

Peak velocity in the fetal MCA

value of greater than 1.5(MoMs) for the corresponding GA

79

Page 80: Antepartum and intrapartum foetal monitoring

80

Page 81: Antepartum and intrapartum foetal monitoring

MCA-PSV for the prediction of severe, moderate, and mild anemia at a sensitivity of 100% showed false-positive rates of 6%, 37%, and 70%, respectively

Measurements can be obtained reliably as early as 18 weeks’ gestation.

Repeated every 1 to 2 weeks depending on the trend.

Values after 35wks higher rate of false-positive results

81

Page 82: Antepartum and intrapartum foetal monitoring

Ductus Venosus

Connects the intra-abdominal portion of the umbilical vein with the inferior vena cava at its inlet to the right atrium.

Shunt plays a critical role in the delivery of well-oxygenated blood to the left side of fetal heart.

Sample siteInlet, where the highest velocities are recorded

waveform of the ductus venosus triphasic.

82

Page 83: Antepartum and intrapartum foetal monitoring

Ductus venosus waveforms

83

Page 84: Antepartum and intrapartum foetal monitoring

Blood flow in the ductus venosus is usually forward in physiological conditions.

In the 11–14 weeks, a negative a-wave may be recorded in about 3% of normal fetuses.

Absolute blood flow velocities increase, whereas the pulsatility decreases with advancing gestation.

This reflecs decreasing cardiac afterload and maturation of diastolic ventricular function.

84

Page 85: Antepartum and intrapartum foetal monitoring

IUGR <32 progressive increase in ductus venosuspulsatility paralleled by decrease of short time variation of the fetal heart rate pattern.

Parameters normal in late-onset growth restriction.

Primary value in early-onset FGR.

Perinatal mortality increases to 38.8% when venous Doppler indices become abnormal.

85

Page 86: Antepartum and intrapartum foetal monitoring

Management goals & protocol Prevention of stillbirth

Delivery based on an accurate assessment of fetal versus neonatal risks.

Abnormal venous Doppler indices, mandate higher testing frequency, up to daily testing.

Reversal of DV a wave increases the risk for an abnormal biophysical profile score within 1 to 8 days.

Reversal of DV a wave only becomes an independent risk factor for neonatal morbidity and mortality after 27 weeks’ gestation.

86

Page 87: Antepartum and intrapartum foetal monitoring

Tests for fetal lungs maturity 1. L/S ratio(>2)

2.Shake or bubble test

3.foam stability index

4.phosphatidyl glycerol

5.amniotic fluid optical density.

6.lamellar body count (>30000/micl

7.amniotic fluid turbidity test

8. Nile blue sulphatase test

87

Page 88: Antepartum and intrapartum foetal monitoring
Page 89: Antepartum and intrapartum foetal monitoring

GOAL The timely identification and rescue of the fetus at

risk of neonatal and long term morbidity from

intrapartum hypoxic insult

Page 90: Antepartum and intrapartum foetal monitoring

Intrapartum monitoring FHR monitoring –

Intermittent auscultation(IA)

Electronic fetal monitoring(EFM)

Fetal Scalp pH

Fetal Pulse oximetry

Fetal scalp lactate testing

ST waveform analysis

Page 91: Antepartum and intrapartum foetal monitoring

FETAL HEART RATE MONITORING External FHR monitoring-

Hand-held Doppler ultrasound probe

External transducer

Page 92: Antepartum and intrapartum foetal monitoring

TECHNICAL CONSIDERATIONS Basis for FHR monitoring is beat to beat recording

For practical purposes ,this is possible only when direct fetal electrocardiograms are recorded with a scalp electrode.

Page 93: Antepartum and intrapartum foetal monitoring

Internal FHR monitoring-

Spiral electrode attatched to the fetal scalp with a connection to FHR monitor.

The fetal membranes must be ruptured, and the cervix must be at least partially dilated before the electrode may be placed on the fetal scalp.

Page 94: Antepartum and intrapartum foetal monitoring

Intermittent auscultation In uncomplicated pregnancies .

Doppler better than stethoscope.

Every 15 - 30 minutes in active phase of first stage and every 5 minutes in second stage

Listen in the absence of active pushing and toward the end of the contraction and at least for 30seconds after each contraction

CONTINUOUS EFM No benefit in low risk

Continuous EFM -when risk factors for present

Every 15 minutes in first stage and every 5 minutes during the second stage.

Page 95: Antepartum and intrapartum foetal monitoring

Fetal Assessment : IA & EFM

Surveillence

Acceptable methods

Low-Risk

Pregnancies

High-Risk

Pregnancies

Intermittent Auscultation* Yes Yes (a)

Continuous Electronic Fetal

Monitoring (EFM)

Yes Yes (b)

Evaluation Intervals

First-stage Labour 30 min 15 min (a,b)

Second –stage labour 15 min 5 min (a,c)

•a- before, during and especially after a contraction for 60 sec

•b- includes evaluation in every 15 min

• c- evaluation in every 5 min

Page 96: Antepartum and intrapartum foetal monitoring

INDICATIONS FOR CONTINUOUS EFMAntepartum risk factors- Abnormal Doppler umbilical artery velocimetry Suspected IUGR APH HTN / preeclampsia (current pregnancy) DM Multiple pregnancy Uterine scar / previous CS Iso-immunisation Oligohydramnios / polyhydramnios Maternal medical conditions(including severe anaemia, cardiac

disease, hyperthyroidism, vascular disease, renal disease)

Page 97: Antepartum and intrapartum foetal monitoring

Risk factors during labour-

Prolonged rupture of membranes (> 24 hours)

Meconium-stained or blood-stained liquor

Fetal bradycardia

Fetal tachycardia

Maternal pyrexia > 38 ˚C

Chorioamnionitis

Vaginal bleeding in labour

• Prolonged second stage of labour .

Page 98: Antepartum and intrapartum foetal monitoring

Other indications

Any use of oxytocin whether for induction or for augmentation of labour

Before and for at least 20 minutes after administration of prostaglandin

Epidural analgesia (immediately after inserting an epidural block)

Page 99: Antepartum and intrapartum foetal monitoring

Electronic fetal monitoring Various components include

-Baseline

-Variability

-Accelerations

-Decelerations

Page 100: Antepartum and intrapartum foetal monitoring

External fetal monitoringBASELINE

The mean FHR rounded to increments of 5 bpm during a 10-minute segment, excluding:

—Periodic or episodic changes

—Periods of marked FHR variability

—Segments of baseline that differ by more than 25 bpm

The baseline must be for a minimum of 2 minutes in any 10-minute segment

Normal : 110–160 bpm

Tachycardia: > 160 bpm

Bradycardia: <110 bpm

Page 101: Antepartum and intrapartum foetal monitoring

FETAL HEART RATE MONITORING Baseline Variability

Fluctuations in the baseline FHR that are irregular in amplitude and frequency

Visually quantitated as the amplitude of peak-to-trough in bpm.

Absent—amplitude range undetectable

Minimal—0 to5 bpm

Moderate (normal) — 6 to 25 bpm

Marked—> 25 bpm

Page 102: Antepartum and intrapartum foetal monitoring

Short term variability – small changes in fetal beat to beat intervals under physiological conditions

Long term variability- certain periodicity in the direction and size of these changes causes oscillations of fetal heart rate around mean level

Page 103: Antepartum and intrapartum foetal monitoring
Page 104: Antepartum and intrapartum foetal monitoring

moderate variability

Page 105: Antepartum and intrapartum foetal monitoring

Factors affecting variability Normal variability : 98% fetuses not acidotic

Decreased variability: Fetal metabolic acidosis , CNS depressants, fetal sleep cycles, congenital anomalies, prematurity, fetal tachycardia, preexisting neurologic abnormality, betamethasone.

Increased variability (saltatory pattern):Acute hypoxia or cord compression, eg 2nd Stage

Page 106: Antepartum and intrapartum foetal monitoring

ACCELERATION A visually apparent abrupt increase in the FHR

<32 weeks: >10 BPM above baseline for >10 sec

>32 weeks: >15 BPM above baseline for > 15 sec

Prolonged acceleration lasts >2 min but <10 min in duration.

If an acceleration lasts 10 min or longer, it is a baseline change

Page 107: Antepartum and intrapartum foetal monitoring

Early Deceleration Symmetrical gradual decrease and return of the FHR

associated with a uterine contraction

The nadir of the deceleration occurs at the same time as the peak of the contraction.

In most cases the onset, nadir, and recovery of the deceleration are coincident with the beginning, peak, and ending of the contraction, respectively

Page 108: Antepartum and intrapartum foetal monitoring

Caused by fetal head compression

by uterine cervix

Usually seen between 4 and 6 cm of

dilation

Page 109: Antepartum and intrapartum foetal monitoring

Late Deceleration Symmetrical gradual decrease and return of the FHR

associated with a uterine contraction

The deceleration is delayed in timing, with the nadir of the deceleration occurring after the peak of the contraction.

In most cases, the onset, nadir, and recovery of the deceleration occur after the beginning, peak, and ending of the contraction, respectively

Page 110: Antepartum and intrapartum foetal monitoring

Associated with uteroplacental insufficiency

Causes -Maternal hypotension,postmaturity, DM,HTN

Page 111: Antepartum and intrapartum foetal monitoring

Variable Deceleration Visually apparent abrupt decrease in FHR

The decrease in FHR is ≥ 15 bpm , lasting ≥ 15 sec, and <2 minutes in duration.

When variable decelerations are associated with uterine contractions, their onset, depth, and duration commonly vary with successive uterine contractions.

Page 112: Antepartum and intrapartum foetal monitoring

TYPES Typical

Atypical

Slow return to baseline

Prolonged secondary rise in baseline

Loss of variability during deceleration

Continuation at lower baseline

Page 113: Antepartum and intrapartum foetal monitoring

Classification of the severity of variable deceleration MILD-

Deceleration of a duration of <30sec , regardless of depth

Deceleration not below 80bpm , regardless of duration

MODERATE- Deceleration with a level <80bpm

SEVERE- Deceleration to a level <70bpm for >60sec

Page 114: Antepartum and intrapartum foetal monitoring

Prolonged Deceleration Decrease from baseline that is 15 bpm or more, lasting

≥ 2 min but <10 min

If lasts 10 minutes or longer, it is a baseline change

Causes-prolonged cord compression,prolongeduterine hyperstimulation,severe degree of abruptio,eclamptic seizure,following conduction anaesthesia

Page 115: Antepartum and intrapartum foetal monitoring

SINUSOIDAL PATTERN Visually apparent, smooth, sine wave-like undulating

pattern in FHR baseline with a cycle frequency of 3–5 per minute which persists for 20 min or more.

Indicates

severe fetal anemia as occurs in

Rh isoimmunization

Feto maternal hemorrhage

Twin twin transfusion syndrome

severe hypoxia

Page 116: Antepartum and intrapartum foetal monitoring

A

Page 117: Antepartum and intrapartum foetal monitoring

Three-Tiered Fetal Heart Rate Interpretation SystemCategory I- NORMAL acid base status• Baseline rate: 110–160 bpm• Moderate Baseline FHR variability• No Late or variable decelerations• Early decelerations: • Accelerations: +Category II-INDETERMINATE not categorized as Category I or III.Category III-ABNORMAL acid base status-Intervention• Absent baseline FHR variability and any of the following:

—Recurrent late decelerations—Recurrent variable decelerations—Bradycardia

• Sinusoidal pattern

Page 118: Antepartum and intrapartum foetal monitoring
Page 119: Antepartum and intrapartum foetal monitoring

RCOG CLASSIFICATIONBASELINE VARIABILITY DECELERATIO

NACCELERATION

REASSURING 110-160 ≥ 5 bpm None present

NONREASSURING

100-109

161-180

< 5 for ≥40 min

but <90 min

Early decel;

typical variable;

single prolonged ≤ 3min

ABNORMAL <100

>180

sinusoidal ≥ 10 min

< 5 for ≥90 min Late decel;

atypical variable;

single prolonged > 3min

Page 120: Antepartum and intrapartum foetal monitoring

Ancillary tests that can aid in the management of Category II or Category III FHR tracings-

Four techniques are available to stimulate the fetus:

1)fetal scalp sampling,

2) Allis clamp scalp stimulation,

3) vibroacoustic stimulation, and

4) digital scalp stimulation

Page 121: Antepartum and intrapartum foetal monitoring

Standard interventions for NRFS -

Supplemental oxygen

Discontinuation of any labor stimulating agent

Changing maternal position

Resolution of maternal hypotension-hydration.

P/V to determine umbilical cord prolapse, rapid cervical dilation, or descent of the fetal head,ARM

Assessment of uterine contraction .

Tocolytics-in tachysystole with associated FHR changes.

When the FHR tracing includes recurrent variable decelerations -Amnioinfusion

Page 122: Antepartum and intrapartum foetal monitoring
Page 123: Antepartum and intrapartum foetal monitoring

MANAGMENTSuspicious CTG-

If inadequate quality-check contact and connections

If hypercontractility-discontinue oxytocin, consider tocolytics

Maternal tachycardia,pyrexia,dehydration, hypotension

Supine? Epidural? sedation? drugs?

i/v crystalloid bolus; 10 L/min O2

If persistent→ do ancillary tests

Pathological CTG

FBS if feasible

If not feasible-expedite delivery (within 30 min)

Page 124: Antepartum and intrapartum foetal monitoring

Effects of Medications on FHR PatternsNarcotics- decreased variability and accelerationsCorticosteroids- Decreased variability (with beta-methasone but not dexamethasone)Magnesium sulfate- A significant decrease in short-term variability, clinically insignificant

decrease in FHR inhibits the increase in accelerations with advancing gestational age

Epidural analgesia- decreased variability and accelerationsTerbutaline- Increase in baseline FHR

Page 125: Antepartum and intrapartum foetal monitoring

FETAL SCALP PH In women with "abnormal“ fetal heart rate tracings .

Cervix needs to be 4-5cm dilated and Vx at -1 st or below

pH <7.20 –fetal acidosis: deliver

pH 7.20-7.25 – borderline, repeat in 30 min or deliver if rapid fall

pH > 7.25 – reassuring, repeat if FH abnormality persists

Greater utility of scalp pH is in its high negative predictive value (97–99%).

Page 126: Antepartum and intrapartum foetal monitoring

Contraindications Maternal infection (HIV, hepatitis, HSV) Fetal bleeding disorders (e.g. haemophilia) Prematurity < 34 weeks Face presentation

Page 127: Antepartum and intrapartum foetal monitoring
Page 128: Antepartum and intrapartum foetal monitoring

FETAL PULSE OXIMETRY

Acidosis: O2 sat. <30% for >2min

Approved by FDA for use in fetuses with NRFS in May 2000

The ACOG currently recommends against its use until further studies are available to confirm its efficacy and safety

Insufficient evidence for its use as an adjunct or independent of electronic fetal surveillance.

Page 129: Antepartum and intrapartum foetal monitoring

FETAL SCALP LACTATE TESTING Higher sensitivity and specificity than scalp pH

> 4.8 mmol/L : acidosis

Clinical trial that compared the use of scalp pH to scalp lactate level did not demonstrate a difference in the rate of acidemia at birth, Apgar scores, or neonatal intensive care unit admissions

Not recommended for routine use

Page 130: Antepartum and intrapartum foetal monitoring

ST WAVEFORM ANALYSIS Method: STAN S31 fetal heart monitor(USFDA)

Scalp electrodes

The electrical fetal cardiac signal – P wave, QRS complex, and T wave – is amplified and fed into a cardiotachometer for heart rate calculation

Page 131: Antepartum and intrapartum foetal monitoring

Restrict fetal ST waveform analysis to those with non reassuring fetal status on EFM

The use of ST waveform analysis for the intrapartum

assessment of the compromised fetus is not recommended

for routine use at this time.

Page 132: Antepartum and intrapartum foetal monitoring

Thankyou

132